Scott Shadfar
Facial Plastic Surgery Edmond, OK Medical Doctor
NPI 1710148283 CMS profile 349652
4509 Integris Pkwy Ste 350, Edmond, OK 73034
General payments
$58
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Scott Shadfar of Edmond, OK is reported in the CMS Open Payments database as having received $58 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 6th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $23 | 1 | |
| 2021 | General | $12 | 1 | |
| 2019 | General | $23 | 1 |
Beside peers
- Scott Shadfar
- Facial Plastic Surgery median
- Middle half of Facial Plastic Surgery
- National median
In program year 2025, general payments to Scott Shadfar were reported at $23. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.
Show as a table
| Year | Scott Shadfar | Facial Plastic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $23 | $225 | $92–$651 | $163 |
| 2020 | $0 | $132 | $45–$323 | $114 |
| 2021 | $12 | $186 | $67–$558 | $132 |
| 2022 | $0 | $218 | $83–$594 | $149 |
| 2023 | $0 | $237 | $94–$564 | $160 |
| 2024 | $0 | $233 | $104–$575 | $164 |
| 2025 | $23 | $270 | $116–$579 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
265
Drug cost
$1,115
Branded share of claims
8.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cephalexin | Generic | 119 | $677 | |
| Mupirocin | Generic | 33 | $247 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 23 | $92 | |
| Tramadol Hcl | Generic | 74 | $73 | |
| Oxycodone Hcl | Generic | 16 | $26 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 49 billing codesPaid by Medicare
$233,708
Medicare patients
148
Services billed
1,001
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 42% | |
| Ischemic heart disease | 41% | |
| Diabetes | 29% | |
| Atrial fibrillation | 24% | |
| Heart failure | 18% | |
| Chronic kidney disease | 18% | |
| Cancer | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 20 | 28 | $19 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Facial Plastic Surgery in Oklahoma
Related records
Facial Plastic Surgery in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Facial Plastic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.